small molecule drug development

AyuVis Research is developing a platform of immunotherapies using novel small molecules to prevent and treat life-threatening diseases with no current effective therapies, including bronchopulmonary dysplasia (BPD) and pulmonary alveolar proteinosis (PAP). Its small molecules modulate white blood cells to fight inflammation and infection with a balanced immune response, are not hindered by drug resistance, and do not cause immunosuppression. The company reports extensive preclinical research with human clinical trials on the horizon.

immunotherapy researchpreclinical research

Celloram Inc. is a preclinical stage biopharmaceutical company founded in 2018 and located at University Circle, Cleveland, OH. It develops cell therapy and small molecule therapeutics targeting cancer, autoimmune, chronic inflammatory and metabolic disorders, with a pipeline of four therapeutics: Sopprimerex, Protexi, NOVS-100, and CLM-022.

cell therapy developmentpreclinical development

Eikonizo is a therapeutics company developing disease-modifying therapies by creating brain penetrant and peripherally-restricted small molecules to improve the treatment of human disease. Its pipeline focuses on highly selective next-generation small molecule inhibitors of HDAC6, a cytoplasmic lysine deacetylase central to intracellular transport, signaling and proteostasis, aimed at neurodegenerative and cardiorenal diseases.

HDAC6 inhibition

Jace Biomedical (JBI) is a small pharmaceutical company founded by Carl Horn and Deborah Milkowski, PhD, focused on developing novel therapies for proteotoxic diseases of the secretory pathway that have no or limited therapeutic options. Its lead program uses small molecules to upregulate reticulophagy (ER-specific autophagy) and break down toxic protein aggregates in the endoplasmic reticulum, targeting indications such as Alzheimer's disease and Alpha-1 antitrypsin deficiency liver disease.

compound optimizationpre-IND studies